Immanuel-Krankenhaus GmbH — Clinical Trial Site

13 Registered trials

2 Currently recruiting

Organisation

Immanuel-Krankenhaus GmbH

Location

Berlin, Germany

Identifier

ORG-100046180

Address

Lindenberger Weg 19, Buch, 13125, Germany

Departments

#1807:Rheumaklinik Berlin-Buch
#1907: Rheumatologie und Klinische Immunologie
1005: Rheumatologie und klinische Immunologie
1907: Rheumatologie und Klinische Immunologie
2353: Abteilung Rheumatologie und Klinische Immunologie
2353: Immanuel Krankenhaus Berlin, Standort Berlin-Buch
ImmanuelKrankenhaus GmbH, Rheumatologie und Klinische Immunologie
Innere Medizin - Rheumatologie, Klinische Immunologie und Osteologie Standort Berlin-Buch
N/A
Rheumatologie und klinische Immunologie
Standort Berlin-Buch

Clinical trials at this site (13)

Search interface

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A study to test whether nerandomilast helps people with lung fibrosis related to rheumatic diseases Recruiting

2024-512849-17-00 Systemic Autoimmune Rheumatic Diseases associated Inter 5 2025-11-14
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu… Ended

2023-508077-85-00 Polymyalgia Rheumatica 5 2024-11-19
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended

2023-503655-10-00 Systemic Lupus Erythematosus (SLE). 5 2023-11-20
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended

2022-502966-26-01 Sjögren’s syndrome 5 2023-10-27
A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenanc… Ended

2023-509320-17-00 non-radiographic axial spondyloarthritis 6 2023-03-28
Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended

2024-511068-10-00 Sjögren’s Syndrome 5 2022-08-04
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended

2023-505478-14-00 Psoriatic Arthritis 5 2019-05-09
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended

2022-501895-25-00 Polymyalgia Rheumatica 5 2023-09-13
Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended

2024-512856-40-00 Giant Cell Arteritis 5 2022-09-21
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia… Ended

2024-510744-31-00 Giant cell arteritis (GCA) 5 2021-10-06